by John Conrad | Oct 3, 2024 | Member News
Eli Lilly and Company, a leading pharmaceutical giant, has announced plans to invest $4.5 billion in a groundbreaking new facility aimed at revolutionizing drug production and accelerating the development of medicines for clinical trials. The announcement comes as...
by John Conrad | Oct 3, 2024 | Policy News
The Centers for Medicare & Medicaid Services (CMS) has announced significant changes to its drug price negotiation process for the Medicare program. These updates come in response to feedback from patients and pharmaceutical companies following the first round of...
by John Conrad | Oct 2, 2024 | Member News
In a significant development for patients with Primary Biliary Cholangitis (PBC), COUR Pharmaceuticals has announced encouraging results from its Phase 2a clinical trial of CNP-104, a potential game-changer in the treatment of this chronic liver disease. What is PBC?...
by John Conrad | Oct 1, 2024 | Member News
Endotronix, an Edwards Lifesciences company, has announced groundbreaking one-year clinical results for their Cordella Pulmonary Artery (PA) Sensor System, marking a significant advancement in heart failure management. The data, presented at the Heart Failure Society...
by John Conrad | Sep 26, 2024 | Member News
ARCH Venture Partners, the Chicago-based venture capital firm known for its bold bets in biotechnology, has once again demonstrated its commitment to driving healthcare innovation. The firm announced on September 26, 2024, that it has raised $3 billion for its...
